StreetInsider.com News Articles

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:

PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.

Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.

As previously announced, no reimbursement will be made to shareholders.

About PHAXIAM Therapeutics

PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

Wed, 18 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens.
Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext.
As previously announced, no reimbursement will be made to shareholders.
About PHAXIAM Therapeutics
PHAXIAM is a

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

Thu, 12 Jun 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025.
As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets.
The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.
Following this decision, PHAXIAM Therapeutics will request the delisting of its

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

Thu, 12 Jun 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025.
As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets.
The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.
Following this decision, PHAXIAM Therapeutics will request the delisting of its

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

Thu, 12 Jun 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025.
As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets.
The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.
Following this decision, PHAXIAM Therapeutics will request the delisting of its

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

Thu, 12 Jun 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025.
As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets.
The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.
Following this decision, PHAXIAM Therapeutics will request the delisting of its

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

Thu, 12 Jun 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025.
As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets.
The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.
Following this decision, PHAXIAM Therapeutics will request the delisting of its

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

Thu, 12 Jun 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as “the Company” or “PHAXIAM,” a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025.
As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets.
The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator.
Following this decision, PHAXIAM Therapeutics will request the delisting of its

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

Thu, 05 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

Thu, 05 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

Thu, 05 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

Thu, 05 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

Thu, 05 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

Thu, 05 Jun 2025 01:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

Thu, 22 May 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on May 21, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 4, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

Thu, 22 May 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on May 21, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 4, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

Thu, 22 May 2025 12:00:00 -0500

LYON, France--(BUSINESS WIRE)-- Regulatory News:
PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court (“Tribunal des activités économiques de Lyon”) decided, during a hearing held on May 21, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 4, 2025.
At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial